AgingResearch.NewsJoin free

Teitur Trophics

CompanyDenmark

Teitur Trophics develops 2 assets, the furthest in phase 1 (TT-P34 in frontotemporal dementia). Mostly peptide acting on BDNF; based in Denmark.

2
Assets
Furthest stage
Phase 1
Raised
€28m
0
Trials
0
Signals

Pipeline

2

  • TT-P34

    Improves mitochondrial and lysosomal function through a dual mechanism of action.

    Phase 1, Peptide, frontotemporal dementia, Huntington's disease

  • TT-P38

    Boosts endogenous BDNF production in the cochlea to promote neuroprotection and synaptic regeneration.

    Stage not known, Peptide, BDNF

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants1
  • People10
  • Similar companies6

Intelligence